Rescheduling Hydrocodone Combination Products Will Lead to More Responsible Use

Published Online: Monday, January 27, 2014
Follow Pharmacy_Times:
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, argues that rescheduling hydrocodone combination products as Schedule II drugs will introduce limitations that will lead to more responsible prescribing of the drugs and monitoring of their use.
 
This is the ninth in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Reclassifying hydrocodone will not stop the drug from being filled legitimately and sold illegally.
Just a dozen drug ingredients are the culprits behind nearly half of all emergency hospitalizations for unsupervised prescription drug ingestions among young children.
In its statement, NACDS emphasized chain pharmacy’s initiatives to comply with DEA’s “cradle-to-grave” regulation structure.
Supporters of the upcoming rescheduling of hydrocodone combination products believe it will help curb our drug abuse and addiction problem in the United States. I don't think so. This article explains why.
Latest Issues
$auto_registration$